Canaccord Reiterates ‘Buy’ Rating on Hims & Hers with $40 Target as Q2 Revenue Surges 40%
No Comments on Canaccord Reiterates ‘Buy’ Rating on Hims & Hers with $40 Target as Q2 Revenue Surges 40%
August 11, 2026
NEW YORK — Investment bank Canaccord Genuity has reiterated its Buy rating and $40.00 price target on Hims & Hers Health, Inc. (NYSE: HIMS) following the telehealth pioneer’s second-quarter 2026 financial report. Wall Street remains captivated…
